Visgeneer - Asset Resilience Ratio

Latest as of June 2021: 1.34%

Visgeneer (4197) has an Asset Resilience Ratio of 1.34% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

NT$5.80 Million

≈ $182.73K USD Cash + Short-term Investments

Total Assets

NT$433.46 Million

≈ $13.66 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2021)

This chart shows how Visgeneer's Asset Resilience Ratio has changed over time. Check 4197 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Visgeneer's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Visgeneer (4197) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$5.80 Million	1.34%
Total Liquid Assets	NT$5.80 Million	1.34%

Asset Resilience Insights

Limited Liquidity: Visgeneer maintains only 1.34% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Visgeneer Industry Peers by Asset Resilience Ratio

Compare Visgeneer's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.11%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Apogee Therapeutics, Inc. Common Stock NASDAQ:APGE	Biotechnology	47.01%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Beijing Hotgen Biotech Co Ltd SHG:688068	Biotechnology	20.87%

Annual Asset Resilience Ratio for Visgeneer (2013–2021)

The table below shows the annual Asset Resilience Ratio data for Visgeneer.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2021-12-31	1.36%	NT$5.80 Million ≈ $182.73K	NT$427.04 Million ≈ $13.45 Million	-8.53pp
2020-12-31	9.89%	NT$45.67 Million ≈ $1.44 Million	NT$461.96 Million ≈ $14.55 Million	+8.68pp
2019-12-31	1.21%	NT$5.80 Million ≈ $182.73K	NT$480.76 Million ≈ $15.15 Million	-0.08pp
2018-12-31	1.29%	NT$5.80 Million ≈ $182.73K	NT$451.24 Million ≈ $14.22 Million	-0.79pp
2013-12-31	2.08%	NT$6.90 Million ≈ $217.39K	NT$332.39 Million ≈ $10.47 Million	--

pp = percentage points

About Visgeneer

TWO:4197 Taiwan Biotechnology

Market Cap

$8.09 Million

NT$256.84 Million TWD

Market Cap Rank

#27554 Global

#1587 in Taiwan

Share Price

NT$8.51

Change (1 day)

+0.47%

52-Week Range

NT$8.20 - NT$19.00

All Time High

NT$28.80